No Data
Express News | ALX Oncology Holdings Inc - to Start Phase 1 Trial for Alx2004 in Mid-2025
Express News | ALX Oncology Receives Ind Clearance From U.S. FDA for Alx2004, a Novel Egfr-Targeted Antibody-Drug Conjugate
ALX Oncology Receives IND Clearance From U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty With a Hold Rating
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge